Clinical Trials
10 trialsNCT00655395 2019-01-28
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Viron Therapeutics Inc
Phase 1/2 Terminated
NCT00354276 2014-01-10
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00112554 2013-11-06
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00049686 2013-07-18
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Completed
NCT00070538 2013-07-18
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
National Cancer Institute (NCI)
Phase 1 Completed
NCT00083187 2013-07-18
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098436 2013-07-18
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
National Cancer Institute (NCI)
Phase 1 Completed
NCT00304005 2013-07-18
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00521859 2012-07-31
Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00840684 2011-05-13
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed